Clinical Trial Update: Clinical Trial of Combined Fostamatinib and Paclitaxel in Ovarian Cancer [Phase 1]

View source ↗

Summary

This Phase 1 trial evaluated the combination of fostamatinib and paclitaxel in ovarian cancer; the study completed and results were posted on 2024-09-19.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Cancer

Drugs mentioned

• Tavalisse (fostamatinib)
• Taxol (paclitaxel)

Snippet

Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Conditions: Ovarian Cancer | Phase 1 | Status: COMPLETED | Results posted: 2024-09-19